Optimize your drug discovery workflow
Efficient drug discovery requires a powerful, fully integrated data source. Unlock deeper insights faster than ever with CAS Solutions, including the new CAS BioFinder Discovery PlatformTM.
Subscribe to our life sciences newsletter
Efficient drug discovery requires a powerful, fully integrated data source. Unlock deeper insights faster than ever with CAS Solutions, including the new CAS BioFinder Discovery PlatformTM.
Unmatched data, unmatched tools, unmatched results
Our scientist curators have carefully extracted, harmonized, and connected the critical information your team needs to advance drug discovery projects, including key concepts, sequence information, and data points. Weaving this unparalleled breadth of high-quality data and expert curation, our world-class solutions will help you reveal critical insights buried in disparate data.
CAS BioFinder™
Access an integrated data source to find connections between ADME, biomarkers, structural similarities, and more – now including the life sciences capabilities of CAS SciFinder®.
Explore CAS BioFinderCAS STNext®
Search the world’s disclosed scientific and technical research to find any document that could impact your novel drug.
Explore CAS STNextCAS Custom ServicesSM
Partner with our experts to create a custom data management platform finely tuned to your drug discovery insights and workflow.
Explore CAS Custom ServicesOur solutions are fueled by expert insights
Challenges and opportunities in creating authority constructs for life sciences
CAS data experts Nicole Stobart, Jeff Wilson, Ph.D., and Mark Schmidt examine the difficulties and importance of creating new authority constructs to organize life sciences data.
Challenges and opportunities of sequence analysis during drug discovery
Jefferson Parker, Ph.D., NullSet Informatics Solutions, shares the importance of sequence analysis, how AI technologies could improve it, and the key problems that remain.
Challenges and opportunities of structure-activity-relationship (SAR) studies
Ben R. Taft, Ph.D., Via Nova Therapeutics, examines the changes in SAR studies, how new technologies are impacting them, and how current bottlenecks could be addressed.
Challenges and opportunities in discovering novel drugs for “undruggable” targets
Mauro Mileni, Ph.D., and Chris Roth, Ph.D., from Abilita Therapeutics discuss how scientists are leveraging the right technology to fill an innovative drug pipeline.
Challenges and opportunities in protein function prediction for drug discovery
Iowa State University associate professor, Iddo Friedberg, Ph.D., discusses how well current protein function prediction models are performing and more.